Bibliography

  1. “What is Lewy Body Dementia” n.d. National Institute on Aging. Accessed Apr 2018. Retrieved from http://www.nia.nih.gov/health/what-lewy-body-dementia

 

  1. Kim et al. (Oct 2014). Alpha-synuclein biology in Lewy body diseases. Alzheimer’s Research and Therapy. DOI: https://doi.org/10.1186/s13195-014-0073-2

 

  1. Marques and Outeiro. (July 2012). Alpha-synuclein: from secretion to dysfunction and death. Cell Death & Disease. DOI: 10.1038/cddis.2012.94

 

  1. Spencer et al. (Jan 2017). Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy. Acta Neuropathologica Communications. DOI: https://doi.org/10.1186/s40478-016-0410-8.

 

  1. Jellinger and Korczyn. (Jan 2018). Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease? BMC Medicine. DOI: https://doi.org/10.1186/s12916-018-1016-8

 

  1. Velayudhan et al. (Jul 2017). New Therapeutic Strategies for Lewy Body Dementias. Curr Neurol Neurosci Rep. DOI : https://doi.org/10.1007/s11910-017-0778-2

 

  1. Kim et al. (Oct 2014). Alpha-synuclein biology in Lewy body diseases. Alzheimer’s Res Ther. DOI: 10.1186/s13195-014-0073-2

 

  1. Dettmer et al. (Jun 2015). Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nature Communications. DOI: https://doi.org/10.1038/ncomms8314

 

  1. Schmid et al. (Aug 2013). Alpha-synuclein Post-translational Modifications as Potential Biomarkers for Parkinson Disease and Other Synucleinopathies. Mol Cell Proteomics. DOI: 10.1074/mcp.R113.032730

 

  1. Lashuel et al. (Jan 2013). The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. DOI : 10.1038/nrn3406

 

  1. Colom-Cadena et al. (2017). Synaptic phosphorylated α-synuclein in dementia with Lewy bodies. Brain. DOI: https://doi.org/10.1093/brain/awx275

 

  1. Prusiner et al. (Sep 2015). Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism. PNAS. DOI : https://doi.org/10.1073/pnas.1514475112

 

  1. Sano et al. (2017). Prion-Like Seeding of Misfolded α-Synuclein in the Brains of Dementia with Lewy Body Patients in RT-QUIC. Mol Neurobiol. DOI: 10.1007/s12035-017-0624-1

 

  1. Hasegawa, M. (Nov 2016). Molecular Biology of Dementia with Lewy Bodies. Springer, Tokyo. DOI: https://doi.org/10.1007/978-4-431-55948-1_4

 

  1. Jellinger and Korczyn. (Jan 2018). Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease? BMC Medicine. DOI: https://doi.org/10.1186/s12916-018-1016-8

 

  1. Webb et al. (Jul 2003). α-Synuclein Is Degraded by Both Autophagy and the Proteasome. JBC. DOI: 10.1074/jbc.M300227200

 

  1. Miners et al. (Dec 2015). Accumulation of α-synuclein in dementia with Lewy bodies is associated with decline in the α-synuclein-degrading enzymes kallikrein-6 and calpain-1. Acta Neuropathologica Communications. DOI: https://doi.org/10.1186/s40478-014-0164-0

 

  1. Spencer et al. (Sep 2015). A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy. Mol Neurodegener. DOI: 10.1186/s13024-015-0043-6

 

  1. Powers et al. (Dec 2015). Lewy Bodies and the Mechanisms of Neuronal Cell Death in Parkinson’s Disease and Dementia with Lewy Bodies. Brain Pathology. DOI: https://doi.org/10.1111/bpa.12344

 

  1. Brundin and Melki. (Oct 2017). Prying into the Prion Hypothesis for Parkinson’s Disease. J Neurosci. DOI: 10.1523/JNEUROSCI.1788-16.2017
  2. “Lewy Body Dementias and Biomarkers ” n.d. LBDA. Accessed Apr 2018. Retrieved from https://www.lbda.org/go/lewy-body-dementias-and-biomarkers
  3. “Dementia with Lewy Bodies” n.d. Accessed Apr 2018. Retrieved from https://www.alz.org/dementia/dementia-with-lewy-bodies-symptoms.asp